← Back to signals
HAE
HOLDHaemonetics Corporation
Health Care
1.32
PEGY ratio
Rank #269
Why This Matters
This stock appears fairly valued relative to its growth and dividend yield. Strong projected growth of 181.3% annually over 5 years.
HAE is fairly valued at 33.1x earnings with 25.0% capped growth (actual 181.3%) (no dividend) (PEGY 1.32). The stock is priced close to what its growth and income profile would suggest.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 181.3%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-05-29
Valuation
33.1x
P/E Ratio
Growth
181.3%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score1.32
Denominator25.0%
EPS (TTM)$2.05
Market Data
Price$67.81
ExchangeNYSE
S&P 500
What Changed
PEGY Score
1.28→1.32(+0.05)
Rank
#260→#269(9 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only